Table Of Content
1 Introduction
1.1 Market Definition
1.2 Market Scope
2 Research Methodology
2.1 Primary Research
2.2 Research Methodology
2.3 Assumptions & Exclusions
2.4 Secondary Data Sources
3 Market Overview
3.1 Report Segmentation & Scope
3.2 Value Chain Analysis: Organoids and Spheroids Market
3.3 Key Market Trends
3.3.1 Drivers
3.3.2 Restraints
3.3.3 Opportunities
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Threat of Substitution
3.4.4 Threat of New Entrants
3.4.5 Competitive Rivalry
3.5 Market Share Analysis
3.6 Technological Overview
3.7 Top investment pockets
3.7 Impact of COVID-19 on Organoids and Spheroids Market
4 Type Overview
4.1 Introduction
4.1.1 Market Size & Forecast (Value)
4.2 Organoids
4.2.1 Market Size & Forecast (Value)
4.2.2 Neural Organoids
4.2.3 Hepatic Organoids
4.2.4 Intestinal Organoids
4.2.5 Other Organoids
4.3 Spheroids
4.3.1 Market Size & Forecast (Value)
4.3.2 Multicellular tumor spheroids (MCTS)
4.3.3 Neurospheres
4.3.4 Mammospheres
4.3.5 Hepatospheres
4.3.6 Embryoid bodies
4.3.5 Other Spheroids
5 Application Overview
5.1 Introduction
5.1.1 Market Size & Forecast (Value)
5.2 Personalized Medicine
5.2.1 Market Size & Forecast (Value)
5.3 Developmental Biology
5.3.1 Market Size & Forecast (Value)
5.4 Drug Toxicityand Efficacy Testing
5.4.1 Market Size & Forecast (Value)
5.5 Disease Pathology Testing
5.5.1 Market Size & Forecast (Value)
5.6 Regenerative Medicine
5.6.1 Market Size & Forecast (Value)
5.7 Others
5.7.1 Market Size & Forecast (Value)
6 End User Overview
6.1 Introduction
6.1.1 Market Size & Forecast (Value)
6.2 Biotechnology and pharmaceutical industries
6.2.1 Market Size & Forecast (Value)
6.3 Academic & Research Institutes
6.3.1 Market Size & Forecast (Value)
6.4 Hospitals and diagnostic centers
6.4.1 Market Size & Forecast (Value)
6.5 Others
6.5.1 Market Size & Forecast (Value)
7 Regional Overview
7.1 Introduction
7.1.1 Market Size & Forecast (Value)
7.2 North America
7.2.1 North America
7.2.1.1 The U.S.
7.2.1.1.1 By Product
7.2.1.1.2 By Application
7.2.1.2 Canada
7.2.1.2.1 By Product
7.2.1.2.2 By Application
7.2.1.3 Mexico
7.2.1.3.1 By Product
7.2.1.3.2 By Application
7.2.2 Central and South America and the Caribbean
7.2.2.1 By Product
7.2.2.2 By Application
7.2.2.2.1 Brazil
7.2.2.2.1.1 By Product
7.2.2.2.1.2 By Application
7.2.2.2.2 Argentina
7.2.2.2.2.1 By Product
7.2.2.2.2.2 By Application
7.2.2.2.3 The Rest of Central and South America and the Caribbean
7.2.2.2.3.1 By Product
7.2.2.2.3.2 By Application
7.3 Europe
7.3.1 Market Size & Forecast (Value)
7.3.2 Western Europe
7.3.2.1 The U.K.
7.3.2.1.1 By Product
7.3.2.1.2 By Application
7.3.2.2 Germany
7.3.2.2.1 By Product
7.3.2.2.2 By Application
7.3.2.3 France
7.3.2.3.1 By Product
7.3.2.3.2 By Application
7.3.2.4 Spain
7.3.2.4.1 By Product
7.3.2.4.2 By Application
7.3.2.5 Italy
7.3.2.5.1 By Product
7.3.2.5.2 By Application
7.3.2.6 The Rest of Western Europe
7.3.2.6.1 By Product
7.3.2.6.2 By Application
7.3.3 Eastern Europe
7.3.3.1 By Product
7.3.3.2 By Application
7.3.4 The Rest of Europe
7.3.4.1 By Product
7.3.4.2 By Application
7.4 Asia Pacific
7.4.1 Market Size & Forecast (Value)
7.4.2 Japan
7.4.2.1 By Product
7.4.2.2 By Application
7.4.3 China
7.4.3.1 By Product
7.4.3.1 By Application
7.4.4 Australia
7.4.4.1 By Product
7.4.4.2 By Application
7.4.5 India
7.4.5.1 By Product
7.4.5.2 By Application
7.4.6 South Korea
7.4.6.1 By Product
7.4.6.2 By Application
7.4.7 The Rest of Asia-Pacific
7.4.7.1 By Product
7.4.7.2 By Application
7.5 The Middle East & Africa
7.5.1 The Middle East
7.5.1.1 Market Size & Forecast (Value)
7.5.1.2 Saudi Arabia
7.5.1.2.1 By Product
7.5.1.2.2 By Application
7.5.1.3 The UAE
7.5.1.3.1 By Product
7.5.1.3.2 By Application
7.6.1.4 Qatar
7.6.1.4.1 By Product
7.6.1.4.2 By Application
7.6.2 The Africa
7.6.2.1 Market Size & Forecast (Value)
8 Company Profile
8.1 3D Biomatrix
8.1.1 Company Overview
8.1.2 Financial Performance
8.1.3 Recent Developments
8.1.4 Product Portfolio
8.2 3D Biotek LLC
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Recent Developments
8.2.4 Product Portfolio
8.3 AMS Biotechnology (Europe) Limited
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.3 Recent Developments
8.3.4 Product Portfolio
8.4 ATCC
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Recent Developments
8.4.4 Product Portfolio
8.5 Cellesce Ltd
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Recent Developments
8.5.4 Product Portfolio
8.6 Corning Incorporated.
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.3 Recent Developments
8.6.4 Product Portfolio
8.7 Greiner Bio-One
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Recent Developments
8.7.4 Product Portfolio
8.8 Hubrecht Organoid Technology (HUB)
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Recent Developments
8.8.4 Product Portfolio
8.9 Kuraray
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 Recent Developments
8.9.4 Product Portfolio
8.10 Lonza
8.10.1 Company Overview
8.10.2 Financial Performance
8.10.3 Recent Developments
8.10.4 Product Portfolio
8.11 Merck KGaA
8.11.1 Company Overview
8.11.2 Financial Performance
8.11.3 Recent Developments
8.11.4 Product Portfolio
8.12 Thermo Fisher Scientific, Inc.
8.12.1 Company Overview
8.12.2 Financial Performance
8.12.3 Recent Developments
8.12.4 Product Portfolio
8.13 Others
8.13.1 Company Overview
8.13.2 Financial Performance
8.13.3 Recent Developments
8.13.4 Product Portfolio
9 Conclusion & Recommendations
10 Acronyms & Abbreviations
